Roger Ganser, acting CEO, has retired and will continue as chairman of the board of directors...Chromatin also appointed Caroline Kovac and John Hamer to its board of directors...Metabolix Inc., of Cambridge, Mass., named George Kipouras and Kristin Taylor business development managers, and Debra Darby brand director

Anadys Pharmaceuticals Inc., of San Diego, promoted Carol G. Gallagher to senior vice president of corporate development and commercial affairs...Cequent Pharmaceuticals, of Cambridge, Mass., named Johannes Fruehauf director of preclinical and clinical development...Champions Biotechnology Inc., of Arlington, Va., appointed Manuel Hidalgo to its board of directors and as a scientific advisor

Spaltudaq Corp., of Seattle, hired Matthew Moyle as senior vice president, chief development officer and Russ Hawkinson as vice president, finance and administration...WEX Pharmaceuticals Inc., of Vancouver, British Columbia, appointed the following to its scientific advisory board: Charles Berde, Howard Cohen, Patrick du Souich, KyungMann Kim and Edward Sellers

Affectis Pharmaceuticals AG, of Munich, Germany, appointed Jesper Wiklund chief business officer and head of finance...CellCyte Genetics Corp., of Kirkland, Wash., appointed Mark Reys vice president of operations and Mark Hollywood director of quality assurance and quality control...Galenea Corp., of Cambridge, Mass., appointed Mark Benjamin president and CEO

Emergent also promoted R. Don Elsey to senior vice president finance and administration...and said Thomas Zink is assuming responsibility for clinical development in addition to medical affairs...Halozyme Therapeutics Inc., of San Diego, named Randal Kirk and Kathryn Falberg to its board

as president and chief operating officer, and Kenneth Yonika, chief financial officer, secretary and treasurer

Pharmacopeia Drug Discovery Inc., of Princeton, N.J., elected Martin Soeters and Dennis Langer to its board...Pharmacyclics Inc., of Sunnyvale, Calif., appointed Michael Inouye senior vice president of corporate and commercial development...Poniard Pharmaceuticals Inc., of South San Francisco, appointed Ronald Martell president and chief operating officer

AEterna Zentaris Inc., of Quebec City, named Ellen McDonald senior vice president, business operations and chief business officer, and named Nicholas Pelliccione senior vice president, regulatory affairs and quality assurance...Alltracel Pharmaceuticals plc, of Dublin, Ireland, appointed Nick Hart chief financial officer and executive director to the board...Xcellerex Inc., of Marlborough, Mass., appointed Joseph Zakrzewski CEO and director

DiaDexus Inc., of South San Francisco, appointed David Foster chief financial officer and executive vice president, and Dino Alfano executive vice president, sales and marketing...and Boston, appointed Claude Benedict senior vice president, clinical development and regulatory affairs

Neuralstem Inc., of Rockville, Md., appointed Scott Ogilvie and William Oldaker to its board...Craig Ritchie to chief European clinical adviser, and Robert Cherny to head of research...Protherics plc, of London, named Rolf Soderstrom finance director, and promoted President Saul Komisar to its board as an executive director

Kythera Biopharmaceuticals Inc., of Los Angeles, appointed Patricia Walker chief medical officer and vice president, clinical development and regulatory affairs

Axon Labs Inc., of Providence, R.I., appointed David Dickinson CEO and board member...Diamics Inc., of Novato, Calif., named Mitchell Golbus chief medical and technical officer...Genelabs Technologies Inc., of Redwood City, Calif., appointed Leslie Browne and Matthew Pfeffer to its board

and Eldon Smith, vice president, scientific affairs and director, will assume all responsibilities of the position of chief medical officer and head of cardiovascular development

Aeris Therapeutics Inc., of Woburn, Mass., appointed May Orfali vice president for clinical research and medical affairs...Aradigm Corp., of Hayward, Calif., named the following to its new scientific advisory board: Peter Byron, Peter Creticos, Stephen Farr, Phyllis Gardner, Michael Konstan, Michael Powell, Robert Ratner, Adam Wanner and Martin Wasserman

Topigen Pharmaceuticals Inc., of Montreal, appointed company officers Lisa Nolan and Mark Parry-Billings to lead its business development initiatives and pharmaceutical development activities, respectively...ViRexx Medical Corp., of Edmonton, Alberta, appointed Peter Smetek and Michael Marcus to its board

MonoGen Inc., of Montreal, promoted Ted Geiselman to president and CEO...It also named Tim Warner senior vice president, investor relations and corporate affairs...Stephan Herrera senior director, investor relations and corporate affairs

plc, of Dublin, Ireland, is bringing on Floyd Bloom and Jeff Shames as non-executive members of the board...Emisphere Technologies Inc., of Tarrytown, N.Y., appointed Michael Novinski president and CEO...Icagen Inc., of Research Triangle Park, N.C., appointed Christopher Cimarusti and Ian Skidmore as the initial members of a new drug discovery and development expert panel

Sapphire Therapeutics Inc., of Bridgewater, N.J., promoted William Polvino from executive vice president to president and CEO

Asterand plc, of Royston, UK, appointed Martyn Coombs CEO and director...Epiphany Biosciences Inc., of San Francisco, made six appointments to its board: Charles Sanders, Clyde Turner, John Quelch, Paul Mieyal, Lee Meisel and Fred Volinsky, Epiphany's CEO, who will serve as chairman